FDC Ltd

531599

Summary

Fair Value Assessment
Undervalued (14% Discount)
Fair ValueQ461.73UncertaintyHigh
Close Price394.30Mar 28, 2025
Market Closed
394.30
Price Down by 0.35 | 0.09 %
Previous Close
394.30
Day Range
390.15 – 402.80
Year Range
364.25 – 659.00
Bid / Ask
Market Cap
64.2 Bil
Volume / Average
4.8 k / 6.8 k
Beta (5-Year)
0.78
Shares Outstanding
162.81 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
FDC Ltd is principally engaged in the business of manufacturing and trading pharmaceutical products. It has its presence in numerous therapeutic segments including anti-infectives, gastrointestinal treatments, ophthalmics, vitamins, minerals, dietary supplements, cardiovascular solutions, anti-diabetics, and others. The company's different pharmaceutical products are marketed through brands such as Electral, Enerzal, Zifi, Zocon, Vitcofol, Otek Ac Neo, Amodep AT, Simyl MCT Oil, and many others. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and other regions.
Contact
106 A, J. P. Road C-3 Skyvistas, Mumbai, MH 400053
T +91 2269107100
www.fdcindia.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Dec 31, 2024
Fiscal Year End
Mar 31, 2025
Employees
6,777

Key Metrics

Income Statement (in Bil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Revenue
20.71 19.35 17.78 15.23 13.23 13.36
Revenue Growth %
8.42% 8.85% 16.71% 15.13% -0.93% 23.40%
Gross Profit
13.14 12.51 10.94 9.76 8.96 8.99
Gross Profit Margin %
63.47% 64.64% 61.54% 64.06% 67.73% 67.30%
Operating Income
2.77 2.99 2.14 2.17 2.96 2.80
Operating Margin %
13.36% 15.43% 12.02% 14.23% 22.39% 21.00%
EBIT
3.43 3.69 2.38 2.69 3.79 3.15
EBIT Margin %
16.54% 19.09% 13.36% 17.65% 28.61% 23.61%
EBITDA
3.91 4.09 2.76 3.06 4.16 3.53
EBITDA Margin %
18.89% 21.15% 15.55% 20.10% 31.46% 26.41%
Net Income
2.74 3.05 1.94 2.16 3.01 2.40
Net Profit Margin %
13.25% 15.76% 10.90% 14.19% 22.76% 17.96%
Basic EPS
16.72 18.59 11.67 12.82 17.72 13.94
Diluted EPS
16.72 18.59 11.65 12.82 17.72 13.94
Normalized EPS
14.40 15.86 10.99 11.02 14.88 14.13
Total Dividends per Share
5.00 0.80
Balance Sheet (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Total Assets
26.88 24.68 23.43 22.70 19.56 18.13
Total Liabilities
3.96 3.71 3.62 3.14 2.22 2.65
Total Debt
0.20 0.21 0.28 0.32 0.15 0.15
Total Equity
22.92 20.97 19.81 19.56 17.34 15.47
Cash And Cash Equivalents
0.44 0.25 0.24 0.38 0.30 0.30
Working Capital
8.17 7.56 7.15 7.28 7.30 6.81
Shares Outstanding (Bil)
0.16 0.16 0.17
Book Value Per Share
128.81 119.47 115.92 102.73 90.51
Total Debt To Equity
0.01 0.01 0.01 0.02 0.01 0.01
Cash Flow Statement (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
3.20 2.21 1.55 1.62 2.07 2.50
Cash From Investing Activities
-2.87 -0.17 0.11 -1.45 -0.77 -0.98
Cash From Financing Activities
-0.11 -2.02 -1.80 -0.10 -1.29 -1.42
Capital Expenditures
0.93 1.13 1.33 0.63 0.31
Free Cash Flow
1.47 0.71 0.50 1.83 2.27
Change in Cash
0.22 0.02 -0.14 0.07 0.01 0.10

Profile

Name (Age)
5-Year Trend
2021
2022
2023
2024
2025
Ameya Ashok Chandavarkar (46) Director and Chief Executive Officer, International Business
Mohan Anand Chandavarkar (—) Director and Managing Director
Nandan Mohan Chandavarkar (—) Director and Joint Managing Director
Total Compensation for all Key Executives
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
No Data Available
There is no available information for this investment.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
No Data Available
There is no available information for this investment.

Ownership

Name
% Total
Shares Held
% Total
Assets
Trend
Prev. 8 Qtrs
Change Amount
Change %
Date
Nippon India Small Cap Gr 2.61 0.32 4,257,262
Feb 28, 2025
ICICI Pru Smallcap Gr 1.02 0.92 1,661,231
6,961
0.42%
Feb 28, 2025
ICICI Pru Pharma Healthcare Diag Gr Not Rated 0.74 0.99 1,197,689
Feb 28, 2025
ICICI Pru Multicap Gr 0.47 0.23 763,541
292,041
61.94%
Feb 28, 2025
ICICI Pru ESG Exclsnry Strtgy Reg Gr 0.34 1.58 559,323
Feb 28, 2025
Total (for Top 5) 5.18 8,439,046
299,002

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top